Efficacy of vonoprazan-based dual therapy and vonoprazan-based triple therapy for Helicobacter pylori eradication: A prospective randomized study
Phase 4
Completed
- Conditions
- Helicobacter pylori infectionvonoprazan, dual therapy, triple therapy, Helicobacter pylori eradication
- Registration Number
- TCTR20210623008
- Lead Sponsor
- Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Inclusion criteria for patients were: patients between the ages of 18 and 70 years old diagnosed as non-ulcer dyspepsia based on the results of esophagogastroduodenoscopy (EGD) and had positive tests for H. pylori infection.
Exclusion Criteria
The exclusion criteria included patients who previously had received H. pylori treatment therapy; who had received antibiotics, bismuth, and/or PPIs/P-CAB within the preceding 4 weeks before the enrollment, had allergy to given drug in the regimens, previously had cardiac arrhythmia including QTc prolongation, who underwent gastric surgery or who were pregnant or breastfeeding women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori eradication rate at least 4 weeks after treatment percentage
- Secondary Outcome Measures
Name Time Method Adverse event at least 8 weeks after treatment Percentages